Vermillion Expects $2M Payment from Bio-Rad Following Patent Re-Issue | GenomeWeb
NEW YORK (GenomeWeb News) – The US Patent and Trademark Office has re-issued a patent covering SELDI mass spec-related technology to Vermillion, formerly called Ciphergen, that entitles the diagnostics developer to a $2 million payment from Bio-Rad Laboratories, Vermillion said today.
 
Bio-Rad agreed to the payment when it bought Vermillion’s proteomics tools business a year ago for $20 million in cash and a $3 million investment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.